Cargando…
Increased Risk of Tourette Syndrome with Leukotriene Modifier Use in Children with Allergic Diseases and Asthma: A Nationwide Population-Based Study
(1) Background: Cysteinyl leukotriene receptor antagonists (LTRAs), including montelukast and zafirlukast, are FDA-approved for treating pediatric asthma and allergic diseases. Tourette syndrome (TS), a common neuropsychiatric disorder in children, is associated with allergic diseases and asthma. In...
Autores principales: | Tsai, Min-Lan, Lin, Hsiu-Chen, Yen, Chiung-Hui, Ku, Jung-Tzu, Sung, Shian-Ying, Chang, Hsi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688072/ https://www.ncbi.nlm.nih.gov/pubmed/36360335 http://dx.doi.org/10.3390/children9111607 |
Ejemplares similares
-
Role of Leukotrienes and Leukotriene Modifiers in Asthma
por: Montuschi, Paolo
Publicado: (2010) -
Genome-wide association study of leukotriene modifier response in asthma
por: Dahlin, A, et al.
Publicado: (2016) -
Managing Co-Morbid Asthma With Allergic Rhinitis: Targeting the One-Airway With Leukotriene Receptor Antagonists
por: Valovirta, Erkka
Publicado: (2012) -
Adipokines and Cysteinyl Leukotrienes in the Pathogenesis of Asthma
por: Coffey, Michael J., et al.
Publicado: (2015) -
Leukotrienes as Modifiers of Preclinical Atherosclerosis?
por: Riccioni, Graziano, et al.
Publicado: (2012)